Harvard Apparatus Regenerative Technology, Inc. (OTC:HRGN)
| Market Cap | $38.68M+4.0% |
| Revenue (ttm) | $1.00M |
| Net Income | -$6.45M+1.2% |
| EPS | -$0.38+0.5% |
| Shares Out | 20.09M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,200 |
| Open | $1.90 |
| Previous Close | $1.90 |
| Day's Range | $1.90 - $1.93 |
| 52-Week Range | $0.96 - $2.46 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About HRGN
Harvard Apparatus Regenerative Technology Inc., a biotechnology firm currently conducting clinical trials, is dedicated to developing regenerative medical therapies. Its core mission involves addressing conditions affecting the gastrointestinal system and various other organs, which may stem from cancer, trauma, or congenital defects. The company's primary experimental therapy, the Cellspan Esophageal Implant, aims to treat severe esophageal disease. Beyond this, its development pipeline encompasses organ-regeneration technologies designed for the repair or replacement of damaged or diseased organs. This includes product candidates targeting diverse esophageal ailments—such as those caused by traumatic injury, caustic burns, or tissue damage from chemoradiation therapy, as well as birth defects—and solutions for colon and uterine wound reconstruction. Additionally, the company offers consumer health products, including dietary supplements, focusing on personal wellness. Founded in 2009 and headquartered in Holliston, Massachusetts, the company operated as Biostage, Inc. until its rebranding to Harvard Apparatus Regenerative Technology Inc. in July 2023.
Harvard Apparatus Regenerative Technology, Inc. Stock Analysis — InsiderScore
Harvard Apparatus Regenerative Technology, Inc. scored higher than 43% of companies evaluated by InsiderBuying, and ranked 43rd out of 102 stocks in the biotech sector.
Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.
Insiders at Harvard Apparatus Regenerative Technology, Inc. bought $394.5K of stock across 2 purchases in the last 90 days, the largest of them $380.0K.
The average purchase added about 18% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.
Every buyer already held stock, so each purchase is an increase rather than a first position.
This category carries 35% of the Insider Score.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$HRGN stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in HRGN holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by HRGN's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
HRGN Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New HRGN patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to HRGN from public contracts
Source: USAspending.gov
Bull Case vs Bear Case
AI-generated from HRGN’s recent data — informational, not investment advice
What’s Behind the Score
Recent Insider Activity
Insider Score Trend Over Time
-21.6 since Sep 26Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
